For the year ending 2025-12-31, TARA had -$113,141K decrease in cash & cash equivalents over the period. -$56,459K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | -57,439 |
| Stock-based compensation | 3,826 |
| Operating lease right-of-use asset | 1,081 |
| Depreciation | 362 |
| Realized loss (gain) on redemption of marketable debt securities | 9 |
| Amortization of premium (accretion of discount) on marketable debt securities | -1,245 |
| Prepaid expenses and other current assets | 2,087 |
| Other assets | -322 |
| Accounts payable | -873 |
| Accrued expenses and other current liabilities | 821 |
| Operating lease liabilities | -1,124 |
| Net cash provided by (used in) operating activities | -56,365 |
| Purchase of marketable debt securities | 204,631 |
| Proceeds from maturity and redemption of marketable debt securities | 65,234 |
| Purchase of property and equipment | 94 |
| Net cash provided by (used in) investing activities | -139,491 |
| Proceeds from exercise of underwriters option in december 2024 public offering, net of offering costs of 214 | 2,528 |
| Offering costs paid in connection with the december 2024 public offering | 614 |
| Proceeds from exercise of warrants | 1 |
| Proceeds from december 2025 public offering, net of offering costs of 5,286 | 80,964 |
| Proceeds from exercise of stock options | 21 |
| Taxes paid related to net share settlement of restricted stock units | 185 |
| Net cash provided by (used in) financing activities | 82,715 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | -113,141 |
Protara Therapeutics, Inc. (TARA)
Protara Therapeutics, Inc. (TARA)